fasudil has been researched along with Intracranial Arteriovenous Malformations in 1 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
Intracranial Arteriovenous Malformations: Congenital vascular anomalies in the brain characterized by direct communication between an artery and a vein without passing through the CAPILLARIES. The locations and size of the shunts determine the symptoms including HEADACHES; SEIZURES; STROKE; INTRACRANIAL HEMORRHAGES; mass effect; and vascular steal effect.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fasudil-treated Ccm1(+/-)Msh2(-/-) mice had a significantly decreased prevalence of CCM lesions compared with placebo controls." | 1.38 | Fasudil decreases lesion burden in a murine model of cerebral cavernous malformation disease. ( Awad, IA; Ginsberg, MH; Liu, F; Marchuk, DA; McDonald, DA; Shenkar, R; Shi, C; Stockton, RA, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| McDonald, DA | 1 |
| Shi, C | 1 |
| Shenkar, R | 1 |
| Stockton, RA | 1 |
| Liu, F | 1 |
| Ginsberg, MH | 1 |
| Marchuk, DA | 1 |
| Awad, IA | 1 |
1 other study available for fasudil and Intracranial Arteriovenous Malformations
| Article | Year |
|---|---|
Fasudil decreases lesion burden in a murine model of cerebral cavernous malformation disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain; Cerebral Hemorrhage; Enzyme Inhibitor | 2012 |